Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 412

The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.

Acamprosate for alcohol dependence

Open access
Rösner, Susanne, Hackl-Herrwerth, Andrea, Leucht, Stefan, Lehert, Philippe, Vecchi, Simona, Soyka, Michael · 2010 · Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Alcohol dependence is among the main leading health risk factors in most developed and developing countries. Therapeutic success of psychosocial programs for relapse prevention is moderate, but could potentially be increased by an adjuvant treatment with the glutamate antagonist acamprosate. OBJECTIVES: To determine the effectiveness and tolerability of acamprosate in comparison to placebo and other pharmacological agents. SEARCH STRATEGY: We searched the Cochrane Drugs and Alcohol Group (CDAG) Specialized Register, PubMed, EMBASE and CINAHL in January 2009 and inquired manufacturers and researchers for unpublished trials. SELECTION CRITERIA: All double-blind randomised controlled trials (RCTs) which compare the effects of acamprosate with placebo or active control on drinking-related outcomes. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data. Trial quality was assessed by one author and cross-checked by a second author. Individual patient data (IPD) meta-analyses were used to verify the primary effectiveness outcomes. MAIN RESULTS: 24 RCTs with 6915 participants fulfilled the criteria of inclusion and were included in the review. Compared to placebo, acamprosate was shown to significantly reduce the risk of any drinking RR 0.86 (95% CI 0.81 to 0.91); NNT 9.09 (95% CI 6.66 to 14.28) and to significantly increase the cumulative abstinence duration MD 10.94 (95% CI 5.08 to 16.81), while secondary outcomes (gamma-glutamyltransferase, heavy drinking) did not reach statistical significance. Diarrhea was the only side effect that was more frequently reported under acamprosate than placebo RD 0.11 (95% 0.09 to 0.13); NNTB 9.09 (95% CI 7.69 to 11.11). Effects of industry-sponsored trials RR 0.88 (95% 0.80 to 0.97) did not significantly differ from those of non-profit funded trials RR 0.88 (95% CI 0.81 to 0.96). In addition, the linear regression test did not indicate a significant risk of publication bias (p = 0.861). AUTHORS' CONCLUSIONS: Acamprosate appears to be an effective and safe treatment strategy for supporting continuous abstinence after detoxification in alcohol dependent patients. Even though the sizes of treatment effects appear to be rather moderate in their magnitude, they should be valued against the background of the relapsing nature of alcoholism and the limited therapeutic options currently available for its treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd004332.pub2

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 14

  1. Barrias, 1997, Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study, Psiquiatria Clinica, 18, 149
  2. Fuchs, 2002, Acamprosate and psychosocial intervention. An integrative treatment approach for prevention of alcohol dependent patients in Switzerland, Praxis (Bern 1994), 91, 735, 10.1024/0369-8394.91.17.735 · doi:10.1024/0369-8394.91.17.735
  3. Nespor, 2006, Treatment and prevention of alcohol-related problems and evidence based medicine, Casopis Lekaru Ceskych, 145, 964
  4. Rychlik, 2001, Adjuvant drug treatment of alcoholism with acamprosate: between sectorial budgets and disease management, Deutsche Medizinische Wochenschrift, 126, 899, 10.1055/s-2001-16502 · doi:10.1055/s-2001-16502
  5. Hopkins, 2002, Naltrexone and acamprosate: Meta-analysis of two medical treatments for alcoholism, Alcoholism: Clinical and Experimental Research, 26, 130A
  6. International Conference on Harmonisation Guideline for Good ClinicalPractice E6(R1). (http://www.ich.org/LOB/media/MEDIA482.pdf) 1996
  7. Kadden, 1992, Cognitive-Behavioral Coping Skills Therapy Manual: A Clinical Research Guide fro Therapists Treating Individuals with Alcohol Abuse and Dependence, 3
  8. Marlatt, 1985, Relapse prevention
  9. Miller, 1994, Motivational Enhancement Therapy manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence
  10. Nowinski, 1995, Twelve Step Facilitation Therapy manual. A clinical research guide for therapists treating individuals with alcohol abuse and dependence
  11. Pettinati, 2004, Medical Management Treatment Manual. A Clinical Research Guide for MedicallyTrained Clinicians Providing Pharmacotherapy as Part of the Treatment for AlcoholDependence, 2
  12. Skinner, 1984, Alcohol Dependence Scale: Users Guide
  13. Spanagel, 2003, Acamprosate--new preclinical research aspects, MMW, Fortschritte der Medizin, 145 Supplement, 61
  14. The Nordic Cochrane Centre Review Manager (RevMan). 5.0 2008

Cited by

See all 412

Metadata

Authors
Rösner, S., Hackl-Herrwerth, A., Leucht, S., Lehert, P., Vecchi, S., & Soyka, M.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2010-09-07
Volume
2011
Issue
2
Pages
70-2
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1966583118
Cited by
412
References
124
FWCI
18.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.